🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg

Found 20 matching trials

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

PHASE1

This study will evaluate the pharmacokinetics of FF, UMEC and VI administer...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-07-15

Trial ID

NCT01894386

Treatments Being Tested

FF 400 mcg UMEC 500 mcg UMEC 250 mcg VI 100 mcg

Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

PHASE4

The goal of this clinical trial is to determine if triple inhaled therapy w...

Status

Completed

Location

Narongkorn Saiphoklang

Start Date

2025-04-01

Trial ID

NCT06905483

Treatments Being Tested

Budesonide/Glycopyrronium/Formoterol (BGF)Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

PHASE3

A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-10-13

Trial ID

NCT02924688

Treatments Being Tested

FF/UMEC/VI (100/31.25/25) mcg FF/UMEC/VI (100/62.5/25) mcg FF/UMEC/VI (200/31.25/25) mcg FF/UMEC/VI (200/62.5/25) mcg FF/VI (100/25) mcg FF/VI (200/25) mcg Fluticasone/salmeterol (FSC)Albuterol/salbutamol ELLIPTA DPI DISKUS DPI METERED-DOSE INHALER (MDI)

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

N/A

This study looks at data from people with chronic obstructive pulmonary dis...

Status

Completed

Location

eMax health

Start Date

2021-12-17

Trial ID

NCT05169424

Treatments Being Tested

Trelegy Ellipta Stiolto Respimat Tiotropium + Olodaterol (5/5 mcg)Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

The primary purpose of this study is to evaluate lung function and health r...

Status

Completed

Location

GSK Investigational Site

Start Date

2018-06-25

Trial ID

NCT03478696

Treatments Being Tested

budesonide/formoterol albuterol/salbutamol FF/UMEC/VI Placebo to match budesonide/formoterol tiotropium Placebo to match FF/UMEC/VI placebo to match tiotropium ELLIPTA MDI HandiHaler

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The study evaluates the efficacy of fluticasone furoate/umeclidinium bromid...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-06-30

Trial ID

NCT02164513

Treatments Being Tested

fluticasone furoate (FF)vilanterol (VI)umeclidinium bromide (UMEC)

A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma

PHASE3

Despite availability of treatments and published guidelines, subjects may h...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-06-22

Trial ID

NCT03184987

Treatments Being Tested

FF/UMEC/VI 100/62.5/25 mcg FF/UMEC/VI 200/62.5/25 mcg Salbutamol ACQ-7

Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study

PHASE4

The primary purpose of this study is to assess the effectiveness of TRELEGY...

Status

Withdrawn

Location

GSK Investigational Site

Start Date

2019-06-27

Trial ID

NCT03949842

Treatments Being Tested

Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists Fluticasone furoate/umeclidinium/vilanterol

A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The primary purpose of this study is to assess the equivalence of closed tr...

Status

Withdrawn

Location

GSK Investigational Site

Start Date

2016-06

Trial ID

NCT02731846

Treatments Being Tested

Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg Fluticasone furoate 100 mcg + Vilanterol 25 mcg Umeclidinium 62.5 mcg Placebo ELLIPTA inhaler Albuterol/Salbutamol

A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects

PHASE1

This is an open-label study to evaluate the PK of FF/UMEC/VI in dose combin...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-09

Trial ID

NCT02837380

Treatments Being Tested

FF VI/UMEC

Previous Next